BioStock: Completion of the recruitment for RhoVac’s Phase IIb study expected in September

RhoVac continued its work on the drug candidate RV001 in the second quarter and was able to present several news items in the project. Results from the long-term follow-up of the Phase I/II study are expected in the autumn, an important milestone pending next year’s results reading in the BRaVac study. BioStock contacted the company’s CEO Anders Månsson to get his view of the quarter passed and what he sees ahead.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/08/completion-of-the-recruitment-for-rhovacs-phase-iib-study-expected-in-september/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se